Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) is projected to announce its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($2.01) per share and revenue of $244.3320 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.48) by $1.58. The company had revenue of $212.80 million during the quarter, compared to analysts’ expectations of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The firm’s quarterly revenue was up 1357.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($7.10) earnings per share. On average, analysts expect Madrigal Pharmaceuticals to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.
Madrigal Pharmaceuticals Stock Performance
Shares of MDGL opened at $415.95 on Thursday. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17. The stock has a market cap of $9.23 billion, a P/E ratio of -32.37 and a beta of -1.02. The company has a 50-day moving average of $428.62 and a two-hundred day moving average of $346.46. Madrigal Pharmaceuticals has a 12-month low of $200.63 and a 12-month high of $463.63.
Insider Activity
Hedge Funds Weigh In On Madrigal Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE grew its stake in Madrigal Pharmaceuticals by 12.7% during the second quarter. Bank of America Corp DE now owns 277,221 shares of the biopharmaceutical company’s stock worth $83,898,000 after buying an additional 31,260 shares during the period. BNP Paribas Financial Markets grew its stake in Madrigal Pharmaceuticals by 1,886.1% during the second quarter. BNP Paribas Financial Markets now owns 69,037 shares of the biopharmaceutical company’s stock worth $20,893,000 after buying an additional 65,561 shares during the period. Raymond James Financial Inc. grew its stake in Madrigal Pharmaceuticals by 1.9% during the second quarter. Raymond James Financial Inc. now owns 54,933 shares of the biopharmaceutical company’s stock worth $16,625,000 after buying an additional 1,017 shares during the period. Balyasny Asset Management L.P. grew its stake in Madrigal Pharmaceuticals by 26.8% during the second quarter. Balyasny Asset Management L.P. now owns 34,500 shares of the biopharmaceutical company’s stock worth $10,441,000 after buying an additional 7,285 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Madrigal Pharmaceuticals by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 23,416 shares of the biopharmaceutical company’s stock worth $7,087,000 after buying an additional 471 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have issued reports on MDGL shares. HC Wainwright started coverage on shares of Madrigal Pharmaceuticals in a research report on Thursday, September 4th. They set a “buy” rating and a $500.00 target price for the company. Cowen reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, August 26th. Canaccord Genuity Group boosted their price objective on shares of Madrigal Pharmaceuticals from $428.00 to $526.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Truist Financial started coverage on shares of Madrigal Pharmaceuticals in a research report on Tuesday, October 14th. They issued a “buy” rating and a $580.00 price objective for the company. Finally, TD Cowen boosted their price objective on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a “buy” rating in a research report on Tuesday, August 26th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Madrigal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $532.70.
Check Out Our Latest Report on Madrigal Pharmaceuticals
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Featured Stories
- Five stocks we like better than Madrigal Pharmaceuticals
- 5 discounted opportunities for dividend growth investors
- Archer’s Recent String of Victories Signals a New Phase of Growth
- 3 REITs to Buy and Hold for the Long Term
- 3 Key Stocks Boosting Buybacks Amid Improving Fundamentals
- The How And Why of Investing in Oil Stocks
- The Best AI for Picking Stocks, Ranked by Performance
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.